NovoCure (NASDAQ:NVCR – Get Free Report) is set to issue its quarterly earnings data before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
NovoCure (NASDAQ:NVCR – Get Free Report) last issued its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.09. The business had revenue of $150.40 million for the quarter, compared to the consensus estimate of $135.83 million. NovoCure had a negative return on equity of 45.68% and a negative net margin of 30.67%. The business’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.54) earnings per share. On average, analysts expect NovoCure to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NovoCure Stock Down 0.7 %
NovoCure stock opened at $16.15 on Wednesday. NovoCure has a 1-year low of $10.87 and a 1-year high of $24.74. The business has a fifty day moving average price of $16.98 and a 200-day moving average price of $17.80. The company has a debt-to-equity ratio of 1.81, a current ratio of 6.46 and a quick ratio of 6.22. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -8.92 and a beta of 0.70.
Analysts Set New Price Targets
Check Out Our Latest Report on NVCR
NovoCure Company Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.
See Also
- Five stocks we like better than NovoCure
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- How Investors Can Find the Best Cheap Dividend Stocks
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Top Stocks Investing in 5G Technology
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.